Preliminary Anticonvulsant and Toxicity Screening of Substituted Benzylidenehydrazinyl-N-(6-substituted benzo[d]thiazol-2-yl)propanamides

Table 2

Phase I anticonvulsant evaluation of the synthesized compounds (5a–t).

Compound	Intraperitoneal injection in mice
	MES		scPTZ		Neurotoxicity screen
	0.5 h	4.0 h	0.5 h	4.0 h	0.5 h	4.0 h
5a	100	100	100	300	—	—
5b	300	—	—	—	—	300
5c	—	300	100	—	—	—
5d	100	300	300	—	—	—
5e	300	—	300	—	—	—
5f	100	300	300	—	—	—
5g	300	—	—	—	—	—
5h^*	30	100	100	—	—	—
5i	100	—	100	300	300	—
5j	300	—	300	300	—	300
5k	100	300	—	—	—	—
5l	—	300	—	—	—	—
5m	—	—	300	—	—	—
5n	100	—	300	—	—	300
5o	100	300	—	—	300	—
5p^*	30	30	100	—	—	300
5q	300	300	—	—	—	—
5r	300	—	300	—	300	—
5s	100	300	—	—	—	—
5t	100	—	300	300	—	—
PHY	30	30	—	—	100	100
CBZ	30	100	100	300	100	300

Number of animals in each group () = 4; solvent used-polyethylene glycol; doses of 30, 100, and 300 mg/kg were administered i.p. The figures indicate the minimum dose whereby bioactivity was demonstrated in half or more mice. The (—) indicates an absence of activity at maximum dose administered (300 mg/kg).